semaglutide
5 Surprising Price Shifts After FDA Excludes Semaglutide
Wholesale prices for GLP-1 drugs rose sharply after the FDA removed semaglutide, tirzepatide and liraglutide from its 503B bulk list, forcing patients and insurers to absorb higher out-of-pocket costs. The change pushes pharmacies to buy single-dose kits instead of bulk supplies, altering the economics of obesity treatment across the United